Image

PUlmonary REhabilitation in Patients Suffering From Post-PE Syndrome

Recruiting
18 - 90 years of age
Both
Phase N/A

Powered by AI

Overview

This study is a multicenter, parallel, randomized waitlist-controlled trial that primarily focuses on the short-term benefit of outpatient pulmonary rehabilitation (PR) on patients after acute pulmonary embolism.

Patients will be randomized into an intervention and a control group. The intervention group will receive 6 weeks of outpatient PR, while patients in the other treatment arm will serve as a control. After completion of the randomized study, the second arm will undergo PR as well.

Eligibility

Inclusion Criteria:

  • Post-PE syndrome (except patients previously diagnosed with CTEPH) diagnosed by any of the following:
    • Post-PE functional impairment criteria
    • Post-PE Cardiac Impairment criteria
    • Chronic Thromboembolic Disease criteria
  • Possibility of starting rehabilitation between 12 and 36 weeks after the initial event

    of PE

Exclusion Criteria:

  • CTEPH diagnosis
  • Chronic pulmonary diseases: COPD, interstitial lung diseases, asthma (only patients with severe asthma defined as a FEV1 ≤ 80% will be excluded), a statement on COVID-19 was amended due to the pandemic #
  • Active cancer
  • Pregnancy
  • Myocardial infarction or cardiac surgery one year prior to inclusion
  • Congenital heart disease, congestive heart failure
  • History of stroke
  • Any previous inpatient or outpatient PR

Additional criteria that are absolute contraindications for pulmonary rehabilitation

  • Acute and decompensated disease states with severe functional restrictions of various organ systems (e.g. heart, kidney and liver insufficiency, unstable angina pectoris, hemodynamically unstable arrhythmias, acute spinal cord injury, untreated hormonal disorders, acute psychological disorders)
  • open tuberculosis
  • active infectious diseases and acute inflammatory processes
  • Stressful and time-consuming therapy that significantly impair the ability to rehabilitate (e.g. chemotherapy or radiation therapy after malignancy)
  • Participants who are not sufficiently resilient due to physical or mental impairment and / or cannot be mobilized and therefore cannot actively use the rehabilitation facility
  • lack of motivation for therapy
  • massive incontinence
  • drugs and alcohol addiction

Study details

Pulmonary Embolism

NCT04615130

Medical University of Vienna

14 October 2025

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.